Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -50.56% is 316% below its 5-year average of -12.14%, near the low end of its 5-year range (-74.61%–22.87%).
22.22% below its 12-month average of -41.37%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 18.60%.
EBITDA MARGIN
-50.56%
EBITDA MARGIN AVG TTM
-41.37%
EBITDA MARGIN AVG 3Y
-19.20%
EBITDA MARGIN AVG 5Y
-12.14%
EBITDA MARGIN AVG 10Y
4.17%
EBITDA MARGIN AVG 15Y
2.30%
EBITDA MARGIN AVG 20Y
0.05%
CURRENT VS TTM AVG
-22.22%
CURRENT VS 3Y AVG
-163.30%
CURRENT VS 5Y AVG
-316.31%
CURRENT VS 10Y AVG
-1313.85%
CURRENT VS 15Y AVG
-2299.28%
CURRENT VS 20Y AVG
-92541.57%
OraSure Technologies, Inc.
Market Cap
$261.62M
EBITDA Margin
-50.56%
TTM Avg
-41.37%
3Y Avg
-19.20%
5Y Avg
-12.14%
Market Cap
$261.89M
EBITDA Margin
-243.80%
TTM Avg
-818.13%
3Y Avg
-818.13%
5Y Avg
-1197.02%
Market Cap
$261.24M
EBITDA Margin
-5226.40%
TTM Avg
-5226.40%
3Y Avg
-5226.40%
5Y Avg
-21156.92%
Market Cap
$263.44M
EBITDA Margin
-9077.06%
TTM Avg
-6066.11%
3Y Avg
-4339.03%
5Y Avg
-4339.03%
Market Cap
$264.10M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$264.94M
EBITDA Margin
-768.62%
TTM Avg
-551.06%
3Y Avg
-374.75%
5Y Avg
-290.29%
Market Cap
$258.60M
EBITDA Margin
-1857.26%
TTM Avg
-1020.57%
3Y Avg
-1032.24%
5Y Avg
-903.20%
Market Cap
$265.39M
EBITDA Margin
-7643.91%
TTM Avg
-11162.31%
3Y Avg
-5581.16%
5Y Avg
-3720.77%
Market Cap
$266.63M
EBITDA Margin
-20.52%
TTM Avg
-21.55%
3Y Avg
-22.69%
5Y Avg
-17.32%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OraSure Technologies, Inc. (OSUR) | $261.62M | -50.56% | -41.37% | -19.20% | -12.14% |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $261.89M | -243.80% | -818.13% | -818.13% | -1197.02% |
| Palisade Bio, Inc. (PALI)vs › | $261.24M | -5226.40% | -5226.40% | -5226.40% | -21156.92% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $263.44M | -9077.06% | -6066.11% | -4339.03% | -4339.03% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $264.10M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $264.94M | -768.62% | -551.06% | -374.75% | -290.29% |
| AC Immune S.A. (ACIU)vs › | $258.60M | -1857.26% | -1020.57% | -1032.24% | -903.20% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $265.39M | -7643.91% | -11162.31% | -5581.16% | -3720.77% |
| Treace Medical Concepts, Inc. (TMCI)vs › | $266.63M | -20.52% | -21.55% | -22.69% | -17.32% |
| Anika Therapeutics, Inc. (ANIK)vs › | $256.55M | -4.72% | -1.10% | 6.56% | 4.38% |
Gross Margin
41.4%
EBITDA Margin
-50.6%
Operating Margin
-59.2%
Net Margin
-43.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 18.60% |
| 2026-03-31 | -74.61% |
| 2025-12-31 | -53.99% |
| 2025-09-30 | -49.23% |
| 2025-06-30 | -47.62% |
| 2025-03-31 | -51.77% |
| 2024-12-31 | -30.62% |
| 2024-09-30 | -6.51% |
| 2024-06-30 | 4.73% |
| 2024-03-31 | -1.16% |
| 2023-12-31 | 14.90% |
| 2023-09-30 | 22.87% |
| 2023-06-30 | 4.76% |
| 2023-03-31 | 18.78% |
| 2022-12-31 | 14.94% |
| 2022-09-30 | 10.31% |
| 2022-06-30 | -9.73% |
| 2022-03-31 | -18.50% |
| 2021-12-31 | -9.68% |
| 2021-09-30 | -18.88% |
| 2021-06-30 | 7.35% |
| 2021-03-31 | 20.66% |
| 2020-12-31 | 13.89% |
| 2020-09-30 | 14.22% |
| 2020-06-30 | -26.17% |
| 2020-03-31 | -15.00% |
| 2019-12-31 | 13.73% |
| 2019-09-30 | 6.36% |
| 2019-06-30 | 19.11% |
| 2019-03-31 | -0.64% |
| 2018-12-31 | 28.56% |
| 2018-09-30 | 27.68% |
| 2018-06-30 | 22.06% |
| 2018-03-31 | 18.60% |
| 2017-12-31 | 23.01% |
| 2017-09-30 | 21.31% |
| 2017-06-30 | 20.83% |
| 2017-03-31 | 14.68% |
| 2016-12-31 | 24.08% |
| 2016-09-30 | 23.50% |
| 2016-06-30 | 18.41% |
| 2016-03-31 | 13.93% |
| 2015-12-31 | 17.07% |
| 2015-09-30 | 9.87% |
| 2015-06-30 | 13.69% |
| 2015-03-31 | 4.13% |
| 2014-12-31 | -3.44% |
| 2014-09-30 | 9.00% |
| 2014-06-30 | 15.40% |
| 2014-03-31 | -17.33% |
| 2013-12-31 | 26.80% |
| 2013-09-30 | -1.76% |
| 2013-06-30 | -16.26% |
| 2013-03-31 | -42.46% |
| 2012-12-31 | -19.67% |
| 2012-09-30 | -4.91% |
| 2012-06-30 | -7.67% |
| 2012-03-31 | -8.80% |
| 2011-12-31 | 6.75% |
| 2011-09-30 | -13.25% |
| 2011-06-30 | -7.89% |
| 2011-03-31 | -9.90% |
| 2010-12-31 | -0.11% |
| 2010-09-30 | 5.56% |
| 2010-06-30 | 0.76% |
| 2010-03-31 | -8.51% |
| 2009-12-31 | -12.99% |
| 2009-09-30 | 11.40% |
| 2009-06-30 | -25.94% |
| 2009-03-31 | -5.87% |
| 2008-12-31 | -28.51% |
| 2008-09-30 | -15.45% |
| 2008-06-30 | -16.42% |
| 2008-03-31 | -12.83% |
| 2007-12-31 | -3.55% |
| 2007-09-30 | -1.32% |
| 2007-06-30 | 5.85% |
| 2007-03-31 | 6.23% |
| 2006-12-31 | 7.20% |
| 2006-09-30 | 17.14% |
| 2006-06-30 | 9.97% |
| 2006-03-31 | 8.76% |
| 2005-12-31 | 15.09% |
| 2005-09-30 | 20.99% |
| 2005-06-30 | 8.95% |
| 2005-03-31 | 11.66% |
| 2004-12-31 | 1.15% |
| 2004-09-30 | 0.99% |
| 2004-06-30 | 4.21% |
| 2004-03-31 | 2.19% |
| 2003-12-31 | 8.77% |
| 2003-09-30 | 6.36% |
| 2003-06-30 | 0.94% |
| 2003-03-31 | -5.78% |
| 2002-12-31 | 6.35% |
| 2002-09-30 | 1.90% |
